BriaCell reports influx of cancer fighting CD8+ “killer” T cell into metastatic breast cancer tumors and lymph organs turning ...

I would cautiously say that the mortality rate for newborns diagnosed with sickle cell at birth is decreasing.

The problem of cell phones in school has perplexed Chad Brinkman since he became principal of Delphos-Jefferson High School ...

This pair of posters presented at the 66th American Society of Hematology Annual Meeting & Exposition provides updates on ...

Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated ...

The company highlighted some preclinical data supporting human studies in a poster presented at the ACR Convergence. The ...

Be Biopharma, Inc. ("Be Bio"), a clinical-stage company pioneering engineered B Cell Medicines (BCMs), today announced two key updates at the 66th ASH Annual Meeting in San Diego, CA. These updates ...

Phase 1 results support further evaluation of ALLO-316 in patients with CD70-positive clear cell renal cell carcinoma, according to researchers.

Priothera is investigating the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in patients with ...

University of Cincinnati Cancer Center experts will present abstracts at the 66th American Society of Hematology (ASH) Annual ...

In a meta-analysis, second-generation BTK inhibitors were linked to a significantly low incidence of atrial fibrillation, ...

Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on ...